April 30, 2021


Media Contact:

Deidre McCabe, Director, Office of Communications, 410-767-3536

Charles Gischlar, Deputy Director, Media Relations, 410-767-6491

Maryland Department of Health Resumes Allocation of Johnson & Johnson COVID-19 Vaccine for Week of May 3, 2021 (Week 21)

The Maryland Department of Health (MDH) is resuming allocation of Johnson & Johnson’s Janssen COVID-19 vaccine to health care providers. This is the first week the federal government has made this vaccine available for allocation since prior to the pause implemented by the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).

MDH strongly supports the reintroduction of the Johnson & Johnson vaccine, based on guidance from the CDC and FDA.

“The Johnson & Johnson vaccine is one of our most important tools in the ongoing fight to prevent hospitalizations and deaths associated with COVID-19,” said Dr. Jinlene Chan, MDH’s Deputy Secretary for Health Services. “By resuming allocations of this safe and effective vaccine in Maryland, we continue to bolster our ability to stay ahead of new cases and emerging variants.”

For Week 21, MDH will allocate Johnson & Johnson vaccines based on requests from providers. A total of 13,600 doses will be allocated as follows:

  • 6,800 to hospitals

  • 2,600 to primary care practices

  • 2,400 to independent pharmacies

  • 1,400 to state correctional facilities

  • 400 to local health departments

Johnson & Johnson providers are reminded to follow the guidance outlined in MDH’s Week 21 vaccine bulletin. Additional clinical guidance on administration of the Johnson & Johnson vaccine can be found on the FDA’s web pages. 



The Maryland Department of Health is dedicated to protecting and improving the health and safety of all Marylanders through disease prevention, access to care, quality management and community engagement.